Seroprevalence of six different viruses among pregnant women and blood donors in rural and urban Burkina Faso: A comparative analysis.
A seroprevalence study was carried out of six different human pathogenic viruses, namely human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), human T-cell leukemia virus (HTLV), human herpesvirus type 8 (HHV-8), and dengue virus among pregnant women and blood donors from rural (Nouna) and urban (Ouagadougou) Burkina Faso, West Africa. A total of 683 samples from blood donors (n = 191) and pregnant women (n = 492) were collected from both sites and screened for the different virus infection markers resulting in the following prevalence values for Nouna or Ouagadougou, respectively: HIV 3.6/4.6, anti-HBV core (anti-HBc) 69.6/76.4, HBV surface antigen (HBsAg)14.3/17.3, HCV 2.2/1.5, HTLV 1.4/0.5, HHV-8 11.5/13.5, dengue virus 26.3/36.5. Individuals aged > or =25 years were more likely to be infected with HIV than those below 24 years (P < 0.05). Infection with HIV increased the likelihood of co-infection with other viruses, such as HHV-8, HBV and HTLV. Co-infection studies involving five viruses (HBV-HBsAg, HHV-8, HIV, HCV, and HTLV) showed that 4.8% (33/683) of the studied population were dually infected, with HBsAg+ HHV-8 (13/33), HBsAg+HIV (8/33) and HIV+HHV-8 (8/33) being the most common co-infections. Of the population studied 0.6% (4/683) was triply infected, the most common infection being with HBV+HIV+HHV-8 (3/4). There was no difference in the prevalence of HIV, anti-HBc, HBsAg, HCV, HTLV, and HHV-8 either among blood donors or pregnant women in urban or rural setting, while dengue virus prevalence was relatively lower in rural (26.3%) than in urban (36.5%) Burkina Faso.
Abteilung Virologie, Universitaetsklinikum Heidelberg, Heidelberg, Germany.
Ellen
E
Collenberg
Thierry
T
Ouedraogo
Jean
J
Ganamé
Helmut
H
Fickenscher
Gisela
G
Kynast-Wolf
Heiko
H
Becher
Bocar
B
Kouyaté
Hans-Georg
HG
Kräusslich
Lassana
L
Sangaré
Denis M
DM
Tebit
D000293:Adolescent; D000328:Adult; D000914:Antibodies, Viral / Q000097:blood*; D001782:Blood Donors; D002050:Burkina Faso / Q000453:epidemiology; D015897:Comorbidity; D003715:Dengue / Q000453:epidemiology*; D003716:Dengue Virus / Q000276:immunology*; D005260:Female; D015483:HIV Antibodies / Q000097:blood; D015658:HIV Infections / Q000453:epidemiology*; D015481:HTLV-I Antibodies / Q000097:blood; D015490:HTLV-I Infections / Q000453:epidemiology*; D006526:Hepatitis C / Q000453:epidemiology*; D018937:Hepatitis C Antibodies / Q000097:blood; D006566:Herpesviridae Infections / Q000453:epidemiology*; D019288:Herpesvirus 8, Human / Q000276:immunology*; D006801:Humans; D016399:Lymphoma, T-Cell / Q000453:epidemiology*; D008297:Male; D008875:Middle Aged; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000453:epidemiology*; D016036:Seroepidemiologic Studies
D000914:Antibodies, Viral; D015483:HIV Antibodies; D015481:HTLV-I Antibodies; D018937:Hepatitis C Antibodies